MedTrace Logo

Composition for Treating Uterine Fibroid (SB-UF)

NCT04762316 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-01

No results posted yet for this study

Summary

Pregnenolone \& Pyridoxal Phosphate SB-UF for treating uterine fibroids in women's pregnancies to lose the size of fibroids and to dissolve fibroids.

Uterine fibroids are a very common finding in women pregnancy of reproductive age, fibroids fast grow in the first trimester of pregnancy. SB-UF against the rapid growth of fibroids under the influence of hormones during pregnancy. Use SB-UF to think about regulating stable Oestrogen levels and dissolving fibroids.

This is a substantial insight into disease pathogenesis, with a clear path toward clinical application, which would lead to a substantial advance and perfection in management or public health policy.

Conditions

  • Uterine Fibroids Affecting Pregnancy

Interventions

DRUG

SB-UF

Dosage: -Take 1tablet/2 times/day/in throughout pregnancy.

DEVICE

SB-UF Placebo

Dosage: -Take 1tablet/2 times/day/in throughout pregnancy.

Sponsors & Collaborators

  • TRAN MINH DUC, MD

    collaborator UNKNOWN

  • Trieu, Nguyen Thi, M.D.

    lead INDIV

Principal Investigators

  • Thi Trieu Nguyen, Dr. · Trieu, Nguyen Thi, M.D.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-01-01
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762316 on ClinicalTrials.gov